HER3 is expressed in many normal tissues and in a variety of solid tumors, including non-small cell lung cancer (NSCLC) [1–4], and increased levels of HER3 have been associated with a negative clinical prognosis, including survival in several tumor types [5–8]. Here, ERBB3 is linked to neoplasm.